GSK to pay $1 billion for exclusive license to J&J’s hepatitis B therapy

(Reuters) -GSK will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson’s hepatitis B therapy, the British drugmaker said on Tuesday. JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018. Exclusive rights to the therapy will fuel the expansion of GSK’s own…

Read More

Google’s Parent Company Makes Big Moves: Understanding Their Financial Ups and Downs, and Their $2 Billion Bet on a Hot New AI Startup

In a time where the biggest tech companies are constantly trying to outdo each other, Alphabet (that’s the company that owns Google) recently shared some news about how it’s doing money-wise. And it’s mostly good news! They made more money than people thought they would, with a total revenue of $76.69 billion in the last…

Read More

Two Sigma tells clients of $620 million in unexpected gains, losses -WSJ

(Reuters) – Hedge fund Two Sigma Investments has told clients of $620 million in unexpected gains and losses which resulted from unauthorized adjustments, the Wall Street Journal reported. The Securities and Exchange Commission (SEC) is examining the matter, Sunday’s WSJ report added, citing sources. The SEC declined to comment on the WSJ report when approached…

Read More